H9/HTLV-IIIB (ATCC® CRL-8543)

Organism: Homo sapiens, human  /  Cell Type:: T lymphocyte  / 

Organism Homo sapiens, human
Cell Type T lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2 Cells Contain RETROVIRUS

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Applications
The cells produce HTLV III.
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Genes Expressed
Human T cell leukemia virus III (HTLV III); Human Immunodeficiency virus (HIV)
Cellular Products
Human T cell leukemia virus III (HTLV III); Human Immunodeficiency virus (HIV)
Comments
The cells produce HTLV III.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Culture Conditions
Temperature: 37.0°C
Name of Depositor The United States of America
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
References

Popovic M, et al. Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions. US Patent 4,520,113 dated May 28 1985

Chang SY, et al. The origin of HIV-1 isolate HTLV-IIIB. Nature 363: 466-469, 1993. PubMed: 8502298

Trkola A, et al. Human momoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70: 1100-1108, 1996. PubMed: 8551569

Basic Documentation
References

Popovic M, et al. Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions. US Patent 4,520,113 dated May 28 1985

Chang SY, et al. The origin of HIV-1 isolate HTLV-IIIB. Nature 363: 466-469, 1993. PubMed: 8502298

Trkola A, et al. Human momoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70: 1100-1108, 1996. PubMed: 8551569